Hamps Bio Limited
Incorporated in 2007, Hamps Bio Ltd is in the business of Pharmaceutical Formulation and Freeze-Drying Ingredient Manufacturing and Distribution[1]
- Market Cap ₹ 21.8 Cr.
- Current Price ₹ 25.0
- High / Low ₹ 26.6 / 13.4
- Stock P/E
- Book Value ₹ 9.39
- Dividend Yield 0.00 %
- ROCE -2.81 %
- ROE -7.66 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 81.4 days to 60.8 days
Cons
- Stock is trading at 2.66 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 0.89% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 5.34 | 5.58 | 6.48 | 6.67 | 8.52 | |
| 4.72 | 4.71 | 5.31 | 5.90 | 8.41 | |
| Operating Profit | 0.62 | 0.87 | 1.17 | 0.77 | 0.11 |
| OPM % | 11.61% | 15.59% | 18.06% | 11.54% | 1.29% |
| 0.00 | 0.01 | 0.03 | 0.15 | 0.33 | |
| Interest | 0.19 | 0.18 | 0.15 | 0.14 | 0.25 |
| Depreciation | 0.33 | 0.34 | 0.40 | 0.38 | 0.81 |
| Profit before tax | 0.10 | 0.36 | 0.65 | 0.40 | -0.62 |
| Tax % | -20.00% | 0.00% | 23.08% | 25.00% | 6.45% |
| 0.12 | 0.36 | 0.50 | 0.30 | -0.65 | |
| EPS in Rs | 0.25 | 0.75 | 0.81 | 0.34 | -0.75 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -317% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 1% |
| Last Year: | -8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1.50 | 1.50 | 1.96 | 4.36 | 8.71 |
| Reserves | -0.49 | -0.14 | 1.38 | 4.44 | -0.53 |
| 2.04 | 1.74 | 1.05 | 2.97 | 6.40 | |
| 0.60 | 0.86 | 0.73 | 1.02 | 0.65 | |
| Total Liabilities | 3.65 | 3.96 | 5.12 | 12.79 | 15.23 |
| 2.15 | 2.61 | 2.52 | 2.48 | 7.19 | |
| CWIP | 0.00 | 0.00 | 0.00 | 3.38 | 1.08 |
| Investments | 0.04 | 0.00 | 0.00 | 0.00 | 2.04 |
| 1.46 | 1.35 | 2.60 | 6.93 | 4.92 | |
| Total Assets | 3.65 | 3.96 | 5.12 | 12.79 | 15.23 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.33 | 1.23 | -0.29 | -1.76 | -0.37 | |
| 0.51 | -0.75 | -0.37 | -6.21 | -2.93 | |
| -0.94 | -0.48 | 0.67 | 8.00 | 3.23 | |
| Net Cash Flow | -0.10 | 0.00 | 0.01 | 0.04 | -0.06 |
| Free Cash Flow | 0.87 | 0.44 | -0.65 | -5.48 | -3.59 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 53% | 141% | -12% | -214% | -336% |
Ratios
Standalone / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 47.16 | 49.71 | 55.76 | 65.12 | 51.84 |
| Inventory Days | 94.57 | 75.03 | 264.09 | 452.45 | 296.87 |
| Days Payable | 63.05 | 103.42 | 60.12 | 114.06 | 41.37 |
| Cash Conversion Cycle | 78.69 | 21.32 | 259.73 | 403.51 | 307.34 |
| Working Capital Days | -34.86 | -58.22 | 55.20 | 128.05 | 60.83 |
| ROCE % | 17.56% | 21.36% | 6.68% | -2.81% |
Insights
In beta| Oct 2024 | Mar 2026 | |
|---|---|---|
| Customer Count (Pharma and FDFP) customers |
|
|
| FMCG Division SKU Count (FZYZEY brand) SKUs (freeze-dried products) |
||
| Freeze-dried Production Volume (monthly average) tons per month |
||
| Installed Freeze-drying Capacity (Ankleshwar and Surat) tons per month |
||
| Pharma Division Product Count items (dosage forms) |
||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026.
-
Closure of Trading Window
- Trading window closed from 1 Oct 2026 until 48 hours after half-year results for 30 Sep 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Board Meeting Outcome for Board Meeting Outcome
- Board approved higher remuneration for CMD, WTD, CFO and director on September 9, 2026.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- 19th AGM held on September 9, 2026; shareholders considered FY26 accounts, director reappointment, and office shift.
Business Overview:[1]
HBL is in the business of ethical marketing and distribution of pharmaceutical formulations across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine & nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers.